BioTissue will highlight its expanding scientific portfolio this October at two major industry gatherings: the American Academy of Optometry Annual Meeting in Boston and the American Academy of Ophthalmology Annual Meeting in Orlando.

According to a news release, investigators will present “Effect of Cryopreserved Amniotic Membrane after Corneal Cross-Linking in Keratoconus Patients: A Controlled, Retrospective Study” (Rosetta M, Gupta R) at both meetings. The study evaluated whether Prokera Slim improves outcomes after corneal crosslinking in progressive keratoconus patients. Eyes treated with Prokera Slim showed significantly better 6-month visual acuity recovery and fewer postoperative complications compared to those who were managed with a bandage contact lens alone. 

The press release also described 3 posters that will be available at the American Academy of Optometry meeting. They demonstrate cryopreserved amniotic membrane (CAM)’s clinical versatility in treating challenging ocular surface conditions:

1. “Hydrated, Shelf-Stable Cryopreserved Amniotic Membrane for the Treatment of Recalcitrant Dry Eye and Reduced Corneal Sensitivity” (Ciarmiello G) describes a patient with chronic dry eye and reduced corneal sensitivity who received 2 days of treatment with CAM360 AmnioGraft (CAM360 AG) in both eyes. Improvements in corneal staining, sensitivity, and visual acuity were maintained for 6 months, and greater comfort was achieved using a collagen shield rather than a bandage contact lens.

2. “Treatment of Glaucoma-Induced Neurotrophic Keratopathy with Shelf-Stable and Hydrated Cryopreserved Amniotic Membrane” (Hoang K) details the case of a patient with glaucoma and persistent ocular surface disease. Following 3 days of CAM360 AG treatment, corneal staining resolved and the patient reported significant improvement in visual stability and irritation within 1 week.

3. “24-hour Treatment with Aggressive Lubrication, Cryopreserved Amniotic Membrane, and a Bandage Contact Lens for Exposure Keratopathy Secondary to Lagophthalmos” (Lazar I) reports a case of incomplete eyelid closure that was unresponsive to standard therapy. After 24 hours of CAM360 AG treatment combined with lubrication and a bandage contact lens, the corneal epithelium fully healed, and the patient experienced clear, comfortable vision 5 days later.

Together, the press release noted, these studies demonstrate the regenerative potential of BioTissue’s CAM technologies across multiple difficult-to-treat ocular surface conditions.

Full program details for the American Academy of Optometry Annual Meeting and the American Academy of Ophthalmology Annual Meeting are available at www.aaopt.org/meetings/academy-2025-boston and www.aao.org/annual-meeting. OM